SCHEMBL3755178

SCHEMBL3755178

COc1ccc2cc(-c3ccccc3)cnc2c1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 3/20 0.52
PDGFRA P16234 3/20 0.52
EGLN3 Q9H6Z9 1/20 0.50
PARP1 P09874 2/20 0.49
KDM4E B2RXH2 1/20 0.48
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
IDO1 P14902 2/20 0.44
TDO2 P48775 2/20 0.44
GAK O14976 2/20 0.43
PDE10A Q9Y233 1/20 0.42
DHODH Q02127 1/20 0.42
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
FYN P06241 2/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3762383 0.79 EGLN3 (0.57) PDGFRBPDGFRAEGLN3MAPT
SCHEMBL3756602 0.76 SLC40A1 (0.52) KDM4ECA12CA1CA2CA7
SCHEMBL3520899 0.75 SMN1; SMN2 (0.55) PDGFRBPDGFRAPARP1CA12CA1
SCHEMBL1073348 0.74 KDM4E (0.67) PDGFRBPDGFRAEGLN3PARP1KDM4E
SCHEMBL30238107 0.74 KDM4E (0.67) PDGFRBPDGFRAEGLN3PARP1KDM4E
SCHEMBL31316511 0.72 KDM4E (0.65) PDGFRBPDGFRAEGLN3PARP1KDM4E
SCHEMBL30238011 0.72 KDM4E (0.65) PDGFRBPDGFRAEGLN3PARP1KDM4E
SCHEMBL28421700 0.72 KDM4E (0.65) PDGFRBPDGFRAEGLN3PARP1KDM4E
SCHEMBL30238255 0.70 PDGFRB (0.69) PDGFRBPDGFRAKDM4EFYN
SCHEMBL17415836 0.70 MAPT (0.58) KDM4ECA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305154-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305154-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 PDGFRB 693/4885PDGFRA 363/4885EGLN3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.